News
Telomir Pharmaceuticals (NASDAQ: TELO) has released new preclinical data showing its lead oral candidate, Telomir-1, reverses key markers of cellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback